301 results on '"SANSONNO, DOMENICO"'
Search Results
2. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
3. Antiviral Therapy in HCV-Positive Non-Hodgkin’s Lymphoma: Pathogenetic Implications
4. PIRR Therapy in HCV-Related Mixed Cryoglobulinemia
5. The Higher Prevalence of B-Cell Non-Hodgkin’s Lymphoma in HCV-Positive Patients with and Without Cryoglobulinemia
6. Role of B-Cell-Attracting Chemokine-1 in HCV-Related Cryoglobulinemic Vasculitis
7. The Pivotal Role of C1qR in Mixed Cryoglobulinemia
8. Introductory Remarks
9. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review
10. HCV-Induced Cryoglobulinemic Vasculitis: Pathogenesis and Therapeutic Implications
11. Treatment of Hepatitis C Virus-Associated Chronic Liver Disease with ß-Interferon and Inosine Pranobex: Combination Schedule vs Monotherapies
12. Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study
13. Validation of the classification criteria for cryoglobulinaemic vasculitis
14. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2
15. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis
16. B-cell depletion in the treatment of mixed cryoglobulinemia
17. Mixed cryoglobulinemia: a model of virus-related disease in internal medicine
18. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations
19. Therapy for Hepatitis C Virus–Related Cryoglobulinemic Vasculitis
20. B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia
21. The Pivotal Role of C1qR in Mixed Cryoglobulinemia
22. Introductory Remarks
23. Role of B-Cell-Attracting Chemokine-1 in HCV-Related Cryoglobulinemic Vasculitis
24. PIRR Therapy in HCV-Related Mixed Cryoglobulinemia
25. Antiviral Therapy in HCV-Positive Non-Hodgkin’s Lymphoma: Pathogenetic Implications
26. The Higher Prevalence of B-Cell Non-Hodgkin’s Lymphoma in HCV-Positive Patients with and Without Cryoglobulinemia
27. Clonal CD27+ CD19+ B Cell Expansion through Inhibition of FCγIIR in HCV+ Cryoglobulinemic Patients
28. Characterization of Antibodies Directed against the Immunoglobulin Light κ Chain Variable Chain Region (VK) of Hepatitis C Virus-Related Type-II Mixed Cryoglobulinemia and B-Cell Proliferations
29. Endocrine manifestations of hepatitis C virus infection
30. Mixed cryoglobulinemia as a model of systemic vasculitis
31. Role of the HLA Class II: HCV-Related Disorders
32. Recent Patents Relating To HCV Molecules Like Putative Targets For Therapeutic Intervention
33. Reply
34. Hepatitis C virus infection and mixed cryoglobulinemia: a striking association
35. HCV-Associated B Cell Clonalities in the Liver Do Not Carry the t(14;18) Chromosomal Translocation *
36. A method for detecting specific anti-C100 protein antibodies of IgM isotype in hepatitis C virus infection
37. Circulating levels and liver tissue distribution of intercellular adhesion molecule-1 during β-interferon therapy of hepatitis C virus-associated chronic active liver disease
38. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
39. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20
40. The Lymphoid System in Hepatitis C Virus Infection: Autoimmunity, Mixed Cryoglobulinemia, and Overt B-Cell Malignancy
41. New Clinical and Molecular Features of “Essential” Mixed Cryoglobulinemia
42. A rapid direct microwave irradiation technique for demonstrating hepatitis C virus-associated C100 protein in formalin-fixed liver tissue
43. In situ simultaneous detection of hepatitis C virus RNA and hepatitis C virus-related antigens in hepatocellular carcinoma
44. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
45. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitor: evidence for a synergistic hematologic toxicity
46. Scelte terapeutiche e trattamento con sorafenib nell'epatocarcinoma: Analisi finale dello studio GIDEON in Italia
47. Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection
48. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
49. Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges
50. Erratum: Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases (PLoS ONE (2015) 10:5 (e0128849) doi:10.1371/journal.pone.0128849)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.